Measles: Comprehensive Disease Characteristics Research Report

1. Disease Information

Overview. Measles (rubeola) is a highly contagious, vaccine-preventable acute viral illness caused by Measles morbillivirus (measles virus, MeV), a member of genus Morbillivirus, family Paramyxoviridae. It is transmitted by respiratory droplets and airborne aerosols, and is characterized by a prodrome of high fever, cough, coryza, and conjunctivitis ("the three C's"), followed by pathognomonic Koplik spots and a cephalocaudally spreading maculopapular rash (CDC Clinical Overview; Mayo Clinic).

Key identifiers: - MeSH: D008457 (Measles) - MONDO: MONDO:0004619 (measles) — note: MONDO:0005453 is a distinct, unrelated entity; do not conflate - ICD-11: 1F03 (Measles) - ICD-10: B05 (Measles) - Wikidata: Q79793 - Related distinct entity: subacute sclerosing panencephalitis (SSPE) has its own Wikidata/MONDO entry (Q2475919), reflecting its status as a delayed complication rather than the acute disease itself

Synonyms: rubeola, morbilli, 9-day measles (to distinguish from rubella/"3-day measles").

Evidence base: Measles is unusual among rare/infectious disease KB entries in that most curative literature is aggregated epidemiological, clinical-cohort, and experimental (NHP) data rather than individual EHR-level case data, though outbreak investigations (e.g., CDC MMWR, Ethiopia outbreak reports) report patient-level line-lists.

Sources: Measles - MalaCards, Mondo Disease Ontology, 1F03 Measles - ICD-11 MMS, IGVF — MONDO:0005453

2. Etiology

Causal agent. Measles is caused exclusively by infection with measles virus (MeV), a non-segmented negative-sense single-stranded RNA virus of genus Morbillivirus. There is no genetic (Mendelian) cause — measles is a purely infectious disease, though host genetics modulates susceptibility and vaccine response (see below).

Risk factors: - Lack of immunity / unvaccinated status: the dominant risk factor. In the 2025 US outbreaks, 93% of confirmed cases occurred in unvaccinated individuals and 3% in under-vaccinated individuals (CDC MMWR 2025; ASTHO 2026). - Age: infants too young for vaccination (<12 months) and adults >20 years are at higher risk of complications (CDC Clinical Overview). - Malnutrition and vitamin A deficiency: strongly associated with severe/fatal disease. "Serum retinol is typically low in measles infection and is inversely related to the severity of the disease" (PMID:1285727 — Vitamin A levels and severity of measles, New York City). Vitamin A deficiency and malnutrition are recognized risk factors for severe measles even in adults in high-income settings (PMID:3437709 — Roma community Europe). - Immunodeficiency: HIV infection, hematologic malignancy, and other immunocompromising conditions predispose to atypical, prolonged, and severe disease including measles inclusion body encephalitis (MIBE). - Pregnancy: increases risk of severe maternal illness and adverse pregnancy outcomes (fetal loss, preterm birth) (Mayo Clinic). - Genetic/host factors (modulating vaccine response and possibly susceptibility, not causal): polymorphisms in RARA/RARB/RARG (vitamin A receptor genes) and VDR (vitamin D receptor) are associated with variation in measles-vaccine antibody titers and cytokine responses (PMID:22082653 — "The RARB haplotype was significantly associated with variations in both measles antibody levels and cytokine secretion, including interleukin (IL)-10 and interferon (IFN)-α"); additional associations reported for cytokine receptor, toll-like receptor, and viral receptor gene variants (PMC3941984).

Protective factors: - Two-dose MMR vaccination (see Prevention). - Maternal antibody transfer confers passive protection in early infancy (waning by ~6-12 months, a key determinant of vaccine-schedule timing). - Adequate vitamin A status. - Prior natural infection (though this carries substantial morbidity/mortality risk itself and induces "immune amnesia" — see Mechanism).

Gene-environment interactions: Vitamin A/D receptor genotype interacts with nutritional vitamin A status to determine antibody response magnitude and durability after vaccination or natural infection — a clear gene-environment interaction relevant to global vitamin-A-deficient populations.

Sources: Vitamin A levels and severity of measles - PubMed, Severe Measles, Vitamin A Deficiency, and the Roma Community, Effects of Vitamin A and D Receptor Gene Polymorphisms on Immune Responses to Measles Vaccine - PMC, Genetic polymorphisms in host antiviral genes - PMC

3. Phenotypes

Quality of life impact: Acute measles causes several days to weeks of debilitating febrile illness with school/work absence; complications (pneumonia, encephalitis) can cause lasting disability (neurological sequelae in ~25% of encephalitis survivors per general pediatric ID literature). SSPE and MIBE are uniformly fatal, progressive neurodegenerative conditions with severe QoL impact (progressive cognitive decline, myoclonus, coma). Immune amnesia is associated with elevated all-cause childhood mortality for 2-3 years post-measles due to loss of protection against unrelated pathogens (broader epidemiological literature, e.g., Mina et al. context).

Sources: Koplik spots in early measles - PMC, Koplik spots revisited - PMC, CDC Clinical Overview, ECDC Disease information on measles, Measles associated with numerous complications, death - AAP, Measles Encephalitis: Towards New Therapeutics - PMC

4. Genetic/Molecular Information

Measles is not a Mendelian genetic disease; "genetic/molecular" information centers on the viral genome rather than host pathogenic variants.

Viral genome and gene products: MeV is a non-segmented negative-strand RNA virus (~16 kb genome) encoding six structural proteins from the 3'→5' gene order N-P/V/C-M-F-H-L: - N (nucleoprotein): encapsidates genomic RNA, forms nucleocapsid with P and L - P (phosphoprotein): polymerase cofactor; the P gene also encodes two nonstructural accessory proteins via RNA editing/alternative ORFs — V and C proteins, both key interferon antagonists - M (matrix): links nucleocapsid to envelope during assembly; mutations in M are central to SSPE pathogenesis (below) - F (fusion): mediates membrane fusion/cell-cell fusion (syncytia) - H (hemagglutinin): receptor-binding envelope glycoprotein; determinant of tropism, binds CD46, SLAM/CD150, and nectin-4 - L (large protein): RNA-dependent RNA polymerase (transcription/replication, capping, polyadenylation, methylation)

Sources: Measles Virus - ScienceDirect Topics, Frontiers - Measles Virus Hemagglutinin

Receptors (functional "variant" analog — receptor tropism): - CD150/SLAM (signaling lymphocytic activation molecule): the receptor for wild-type MeV on immune cells; "expressed on activated B, T, monocyte, and dendritic cells" (PMC4997572). HGNC: SLAMF1. - Nectin-4 (PVRL4): the epithelial-cell receptor mediating virus egress via the airway epithelium — "Tumor Cell Marker PVRL4 (Nectin 4) Is an Epithelial Cell Receptor for Measles Virus" (PMC3161989). HGNC: NECTIN4. - CD46: a complement-regulatory protein expressed on all human nucleated cells; used specifically by vaccine and some laboratory-adapted MeV strains, not wild-type virus (PMID:20010840, structural study of MV-H bound to CD46; RCSB 3INB).

Genotypes/molecular epidemiology: WHO recognizes measles genotypes based on N and H gene sequence divergence thresholds (2.5% and 2.0% nucleotide divergence respectively define a new genotype). Of 24 recognized genotypes, only genotypes B3 and D8 have caused the great majority of outbreaks globally in the elimination era (PMC7352894); B3 has further diverged into sub-genotypes 3.1 and 3.2, with 3.2/400V the dominant global clade of the past decade (PMC8540759).

SSPE-associated viral mutations: SSPE virus accumulates extensive hypermutation during chronic CNS persistence, notably clustered mutations in the matrix (M) protein gene that suppress productive budding/infectious particle release and favor cell-to-cell spread by fusion, plus hyperfusogenic mutations in F that facilitate CNS propagation via syncytium formation rather than free virion release (PMC8604190 — "M protein of subacute sclerosing panencephalitis virus, synergistically with the F protein, plays a crucial role in viral neuropathogenicity").

Host genetic modifiers: RARA/RARB/RARG (vitamin A receptor) and VDR (vitamin D receptor) polymorphisms modulate the magnitude of humoral/cellular vaccine response (see Etiology). No host pathogenic-variant classification (ACMG/ClinVar) applies since this is not a genetic disease; there is no somatic/germline distinction relevant here except in the sense of viral quasispecies evolution within a host (SSPE).

Epigenetics: No well-characterized disease-defining host epigenetic signature is established in the literature reviewed; MeV infection does induce host transcriptional reprogramming (interferon-stimulated gene suppression via STAT1/STAT2 antagonism — see Mechanism) but this is a functional/immunological rather than an epigenetic (chromatin) mechanism per se.

Suggested identifiers: HGNC:SLAMF1, HGNC:NECTIN4, HGNC:CD46; GO terms below.

5. Environmental Information

• Infectious agent: Measles morbillivirus (NCBI Taxon:11234), genus Morbillivirus, family Paramyxoviridae. Transmission is via respiratory droplet, aerosol (airborne), and direct contact with infected secretions; the virus remains viable and infectious in airspace/on surfaces for up to 2 hours after an infected person leaves an area (well-established CDC/WHO characterization).
• Environmental/structural factors: crowding, low vaccination coverage in a community (e.g., religious/philosophical exemption clusters — the Dutch Orthodox Protestant outbreak studied in PMC6251901; US 2025 outbreaks concentrated in under-vaccinated communities), healthcare-associated transmission, and international travel-importation into susceptible pockets are the dominant environmental drivers of outbreaks in the current elimination era.
• Lifestyle factors: vaccine hesitancy/refusal is the principal modifiable behavioral determinant of outbreak risk in high-income countries; nutritional status (vitamin A intake) is the principal modifiable factor for severity in low-resource settings.
• No toxin, radiation, or occupational-exposure etiology is applicable — measles is a directly infectious, not environmentally-triggered, disease.

Sources: Studies into the mechanism of measles-associated immune suppression - Nature Communications, MMWR Measles Update 2025, US measles outbreak: causes, consequences - PMC

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream):

1. Respiratory entry & innate immune cell infection: MeV aerosol/droplet exposure infects alveolar macrophages and dendritic cells of the airway, which act as the initial portal (PMC4997572 — "MV infection starts in alveolar macrophages and dendritic cells of the airways, which transport the virus to the lymphoid organs").
2. Lymphatic dissemination: Infected APCs traffic the virus to local lymph nodes and primary/secondary lymphoid organs, where the virus undergoes explosive replication in SLAM/CD150-high activated lymphocytes (memory B and T cells preferentially, due to higher CD150 expression than naive cells) (PMID:33332470; PMC7994291).
3. Systemic viremia and epithelial re-infection: Infected immune cells recirculate systemically and transmit virus back to the respiratory epithelium via the basolateral nectin-4 receptor, enabling apical shedding into airway secretions for onward transmission (PMC3161989; PMC3571369).
4. Innate immune evasion: The P-gene-derived V and C accessory proteins block type I/III interferon signaling — V protein binds JAK1/TYK2 and forms a complex with STAT1/STAT2/IRF9, blocking STAT1-STAT2 heterodimerization and ISG transcription; C protein independently interferes with IFN-β transcription in the nucleus (PMC9781438; JVI.00831-08; JVI.00108-08). This transient global interferon blockade permits systemic viral spread before adaptive clearance.
5. Immune amnesia (the signature downstream immunological lesion): MeV's tropism for CD150-high memory lymphocytes causes selective depletion of pre-existing immunological memory — both memory B cells (loss of IgG+/IgA+ class-switched memory B cells) and memory T cells are preferentially infected and eliminated, while a compensatory rise in naive/transitional B cells reconstitutes a "immunologically naive" repertoire (PMC6251901, Nature Communications 2018, PMID:30470742). The landmark VirScan serological study (Mina et al., Science 2019, PMID:31672891) quantified this directly: "Measles caused elimination of 11 to 73% of the antibody repertoire across individuals," with recovery only via re-exposure, and the effect was absent in MMR-vaccinated children — establishing that natural infection, not vaccination, causes this immunosuppressive erasure.
6. Clinical rash and mucocutaneous manifestation: The maculopapular rash and Koplik spots reflect a cell-mediated immune (T-cell) response attacking virus-infected vascular endothelial and epithelial cells, not direct cytopathic viral effect — rash onset coincides with the appearance of MeV-specific T cells and roughly with viral clearance from blood.
7. Complications as downstream branches:
8. Transient global immunosuppression (steps 4-5) → secondary bacterial/opportunistic infections (otitis media, pneumonia) which cause most deaths.
9. Acute post-infectious encephalitis (~1/1000-2000): thought to be immune-mediated (autoimmune, ADEM-like) rather than direct CNS viral invasion in most cases.
10. SSPE: rare (~1/10,000-100,000, but much higher if infection occurs before age 2) persistent, defective, non-productive CNS infection by a hypermutated MeV variant. Accumulated M-protein mutations suppress virion budding (limiting immune-detectable free virus) while hyperfusogenic F-protein mutations enable cell-to-cell spread within the CNS via syncytia, producing progressive neurodegeneration over years (PMC8604190).
11. MIBE: in severely immunocompromised hosts (HIV, hematologic malignancy, transplant), inadequate T-cell control allows productive-but-contained CNS infection with a fulminant, rapidly fatal course within months.

Cellular processes involved: apoptosis of infected lymphocytes, cell-cell membrane fusion (syncytium formation — GO:0140253 cell-cell fusion), suppression of type I/III interferon signaling (GO:0060337 type I interferon signaling pathway), immune memory cell depletion, bystander immunosuppression, complement regulation interference (via CD46 binding).

Cell types involved (suggested CL terms): - CL:0000235 macrophage (alveolar macrophage entry) - CL:0000451 dendritic cell - CL:0000236 B cell / CL:0000787 memory B cell - CL:0000084 T cell / CL:0000897 CD4-positive, alpha-beta memory T cell - CL:0000066 epithelial cell (respiratory epithelium, nectin-4-bearing) - CL:0000127 astrocyte / CL:0000540 neuron (CNS spread in SSPE/MIBE)

Biological process GO terms: - GO:0019064 fusion of virus membrane with host plasma membrane - GO:0039502 suppression by virus of host type I interferon-mediated signaling pathway - GO:0002250 adaptive immune response (disrupted) - GO:0006915 apoptotic process (infected lymphocyte death)

Molecular profiling: VirScan/phage-immunoprecipitation sequencing (PhIP-seq) has been the key "omics" technology demonstrating repertoire-wide antibody loss (Mina et al. 2019). Immunosequencing (Adaptive Biotechnologies/immunoSEQ-style B/T-cell receptor repertoire sequencing) was used in PMC6251901 to demonstrate reduced memory B-cell receptor diversity post-infection. No large-scale single-cell or spatial transcriptomic atlas specific to measles was identified in this search, though NHP and cotton-rat transcriptomic studies of lymphoid tissue exist in the broader literature.

Sources: Measles Virus Host Invasion and Pathogenesis - PMC, On invariant T cells and measles - PLOS Pathogens/PubMed, Measles immunity and immunosuppression - PMC, Measles Virus-Induced Host Immunity and Mechanisms of Viral Evasion - PMC, STAT2 Is a Primary Target for Measles Virus V Protein - J Virol, Measles Virus Circumvents Host Interferon Response by C and V Proteins - J Virol, Studies into the mechanism of measles-associated immune suppression - Nature Comm, Mina et al. Science 2019;366(6465):599-606, PMID:31672891, M protein of SSPE virus - PMC

7. Anatomical Structures Affected

Organ level: - Primary: respiratory tract (nasopharynx, trachea, bronchi) — site of entry and shedding - Secondary/systemic: lymphoid organs (lymph nodes, spleen, thymus, tonsils — primary sites of viral amplification); skin/mucous membranes (rash, Koplik spots); eyes (conjunctivitis); in complications — lungs (pneumonia), middle ear, GI tract (diarrhea), liver (rare hepatitis), heart (rare myocarditis), CNS (encephalitis, SSPE, MIBE) - Body systems: respiratory, immune/lymphatic, integumentary, and (in complications) nervous, cardiovascular, hepatic, hematologic (thrombocytopenia) systems

Tissue/cell level: - Respiratory pseudostratified columnar epithelium (nectin-4+ basolateral entry/apical egress) - Lymphoid tissue: germinal center B cells, memory T cells, follicular dendritic cells - Vascular endothelium (implicated in rash pathogenesis) - CNS: neurons and astrocytes (SSPE/MIBE; CDV comparative data show SLAM/nectin-4-independent noncytolytic astrocyte spread in the related canine distemper virus, PMC4442543, informative for morbillivirus CNS tropism generally)

Subcellular level (GO Cellular Component): - Plasma membrane (H/F envelope glycoprotein fusion machinery, GO:0005886) - Cytoplasm (nucleocapsid assembly, ribonucleoprotein complex, GO:0019013 viral nucleocapsid) - Nucleus (C protein interferes with IFN-β transcription in the nucleus — JVI.86.2.796)

Localization / laterality: Rash is typically bilateral/symmetric, beginning at the hairline/behind the ears and spreading centrifugally and caudally — no lateralization is expected as this is a systemic, hematogenously/lymphatically disseminated infection.

Suggested UBERON terms: UBERON:0001004 (respiratory system), UBERON:0002370 (thymus), UBERON:0002100 (lymph node), UBERON:0002097 (skin of body), UBERON:0000955 (brain).

8. Temporal Development

Onset: Acute onset, incubation period ~10-14 days (range 7-21) from exposure to first symptoms; prodrome (fever, cough, coryza, conjunctivitis) begins 2-4 days before rash; Koplik spots appear 1-2 days before rash and fade 1-2 days after rash onset. Any unvaccinated/non-immune individual of any age can be affected; classically a childhood disease but adult and neonatal (congenital, via transplacental infection near delivery) cases occur.

Progression/stages: 1. Incubation (asymptomatic, ~10-14 days) 2. Prodromal ("catarrhal") stage (2-4 days): fever, cough, coryza, conjunctivitis, Koplik spots 3. Exanthem stage: maculopapular rash spreads face→trunk→extremities over ~3 days, with fever peaking at rash onset 4. Recovery: rash fades in order of appearance over 5-7 days, with fine desquamation; cough may persist 1-2 weeks 5. Delayed complications: acute post-infectious encephalitis (days-weeks post-rash), MIBE (1-9 months, immunocompromised only), SSPE (4-10 years, range 1 month-27 years)

Course pattern: Self-limited acute monophasic illness in the immunocompetent host; complications represent distinct temporal branches rather than a relapsing-remitting pattern. SSPE itself, once initiated, is relentlessly progressive (stages from behavioral/cognitive decline through myoclonus to akinetic mutism and death, classically over 1-3 years, though acute fulminant and very protracted forms occur).

Critical periods: Age at primary infection strongly determines SSPE risk — infection before age 2 confers markedly higher SSPE risk than infection later in childhood (well-established in the SSPE literature, e.g., PMC12145622 case series on SSPE re-emergence with low vaccination coverage). The maternal-antibody window (birth to ~12 months) is the critical period determining first MMR dose timing.

Remission: No spontaneous remission pattern applies to acute measles (self-limited by adaptive immunity) or SSPE (uniformly progressive, no spontaneous remission; rare prolonged plateau phases reported but not true remission).

Sources: Subacute sclerosing panencephalitis as a re-emerging condition - PMC, MedlinePlus - SSPE, Subacute sclerosing panencephalitis (SSPE) associated with congenital measles infection - PubMed

9. Inheritance and Population

Measles is an infectious, not inherited, disease — no Mendelian inheritance pattern, penetrance, expressivity, anticipation, mosaicism, founder effect, or carrier-frequency concepts apply in the genetic sense. Population genetics is relevant only insofar as host genotype (vitamin A/D receptor variants) modulates vaccine response (see Etiology).

Epidemiology: - Global burden: an estimated 11 million measles infections in 2024 — nearly 800,000 more than pre-pandemic 2019 levels (WHO/PAHO, Nov 2025). Measles deaths have fallen 88% since 2000, but cases are surging due to declining vaccination coverage. - Vaccine impact: nearly 59 million lives saved by the measles vaccine since 2000 (WHO 2025). - Elimination status: 96 countries have achieved measles elimination; Canada officially lost its elimination status following prolonged 2024-2025 transmission — the only country in the Americas to do so. - US 2025 outbreak: the worst year for US measles in over three decades — 2,144 confirmed cases, 49 outbreaks, 88% of cases outbreak-associated, 3 deaths confirmed; 93% of cases in unvaccinated individuals. - Global vaccination coverage: first-dose (MCV1) coverage ~83%, second-dose (MCV2) ~74% — both below the 95% threshold needed for herd immunity. - Case fatality rate: 1-3 per 1,000 cases in general, but ranges from 0.1% in industrialized countries to as high as 15% in some developing-country settings, highest in children <5 years and immunocompromised individuals (ECDC). - R0 (basic reproduction number): widely cited as 12-18 (some estimates 6-19+), among the highest of any human pathogen, driving the very high (~92-95%) herd immunity threshold required for elimination.

Population demographics: No strong ethnic/genetic-susceptibility pattern is described (unlike genetic diseases); disparities in incidence instead track vaccination coverage gaps — geographically concentrated in under-immunized communities (religious/philosophical exemption clusters, conflict-affected regions with disrupted health systems, and low-income countries with weaker routine immunization infrastructure). Age distribution has shifted in some outbreak settings toward older unvaccinated cohorts and infants too young for vaccination.

Sources: Measles deaths down 88% since 2000 - WHO, Measles deaths down 88% since 2000 - PAHO, Understanding Current U.S. Measles Outbreaks - ASTHO, Measles Update MMWR, The basic reproduction number (R0) of measles: systematic review - ScienceDirect, Are the Objectives Proposed by WHO Sufficient to Achieve Measles Elimination - PMC

10. Diagnostics

Clinical criteria: Classic triad (fever + cough/coryza/conjunctivitis) plus generalized maculopapular rash plus Koplik spots is highly suggestive; case definitions (WHO/CDC) require laboratory confirmation for surveillance purposes given resurgence of other rash-fever illnesses.

Laboratory tests: - RT-PCR (real-time reverse transcription PCR): highest diagnostic sensitivity when specimens (nasopharyngeal swab, throat swab, urine, or oral fluid) are collected from first contact through ~3 days after rash onset, with detection possible up to 10-14 days after rash onset. Available at state public health labs and the APHL/CDC Vaccine Preventable Disease Reference Centers. - IgM serology: capture IgM EIA using recombinant nucleocapsid protein antigen; presumptive evidence of current/recent infection from serum collected within the first few days of rash. - Combined approach: CDC recommends performing RT-PCR and serology together for all suspect cases. - Genotyping: N/H gene sequencing for molecular epidemiology and outbreak-source tracing (WHO genotype nomenclature, e.g., distinguishing B3/D8). - High-avidity IgG / neutralizing antibody titers: used to distinguish primary infection from reinfection in previously immune individuals (PMC4979181).

Differential diagnosis: rubella, roseola, parvovirus B19 (fifth disease), scarlet fever, Kawasaki disease, drug reactions, other viral exanthems — distinguished by Koplik spots, rash progression pattern, and epidemiologic exposure history.

Screening: No population genetic screening applies (non-genetic disease); public health "screening" takes the form of vaccination-status verification, contact tracing, and outbreak surveillance rather than individual diagnostic screening of asymptomatic persons.

Suggested LOINC/ontology terms: LOINC codes exist for measles IgM/IgG serology and measles RNA PCR panels (specific LOINC codes should be verified via LOINC search at curation time).

Sources: Laboratory Testing for Measles - CDC, Measles Serology Testing - CDC, High Concentrations of Measles Neutralizing Antibodies... Identify Measles Reinfection - PMC, Importance of real-time RT-PCR in measles elimination program - PMC

11. Outcome / Prognosis

Mortality: Case fatality rate 1-3/1000 in general populations; 0.1% in industrialized settings up to 15% in some developing-country outbreak settings; highest in children under 5 and immunocompromised patients. Pneumonia accounts for 56-86% of measles-related deaths (varies by source; one estimate states "six out of ten measles associated deaths"). Encephalitis carries ~10% mortality among those who develop it. SSPE and MIBE are essentially uniformly fatal once established, over a course of months (MIBE) to typically 1-3 years (SSPE, with variable pace).

Morbidity/functional outcomes: Acute encephalitis survivors frequently have permanent neurological sequelae. Immune amnesia produces a period (empirically estimated at up to 2-3 years in broader epidemiological literature, though not itself directly measured in the PMIDs retrieved here) of elevated susceptibility to unrelated infections, contributing to excess non-measles mortality in the months-years following infection — the core translational implication of the Mina et al. 2019 findings.

Recovery potential: Uncomplicated measles is self-limited with full recovery in a large majority of immunocompetent patients; vitamin A supplementation reduces morbidity/mortality in deficient populations (Cochrane review, PMID:16235283 — "Vitamin A for treating measles in children"). Antibody-repertoire loss from immune amnesia is gradually reconstituted upon natural re-exposure to pathogens over time (Mina et al. 2019).

Prognostic factors: age (<5 or >20), nutritional/vitamin A status, immune status (HIV, malignancy, transplant), and vaccination status of the community (affecting secondary attack rates and access to post-exposure prophylaxis) are the dominant prognosis-modifying variables identified in this literature set.

Sources: Vitamin A for treating measles in children - PubMed/Cochrane, Attack rate, case fatality rate and determinants of measles infection - Ethiopia systematic review - PMC, Measles 2025 - NEJM

12. Treatment

Pharmacotherapy: There is no FDA-approved specific antiviral therapy for measles. Ribavirin has in vitro activity and has been used off-label/experimentally in severely immunocompromised patients or severe pneumonia/encephalitis, but is not FDA-approved for this indication and such use is considered experimental (Medscape Treatment).

Vitamin A therapy (MAXO consideration — supportive/nutritional intervention): WHO recommends oral vitamin A, 200,000 IU (100,000 IU for infants) once daily for 2 days, for children with measles, particularly in vitamin-A-deficient settings; the American Academy of Pediatrics extends this recommendation to US children under medical supervision. Cochrane review supports reduced morbidity/mortality with this regimen (PMID:16235283).

Supportive care: the mainstay of management — bed rest, hydration (especially with diarrhea), antipyretics, and prompt treatment of secondary bacterial complications (otitis media, pneumonia) with appropriate antibiotics when indicated.

Passive immunization / post-exposure prophylaxis: immunoglobulin (IG) can be given to high-risk exposed contacts (infants, pregnant women, immunocompromised persons) within 6 days of exposure to prevent or attenuate disease; MMR vaccine can be given within 72 hours of exposure to eligible contacts.

Experimental/emerging approaches: - Fusion-inhibitory peptides delivered by nebulization have protected cynomolgus macaques from measles virus infection in a proof-of-concept animal study ("Nebulized fusion inhibitory peptide protects cynomolgus macaques from measles virus infection," Nature Communications, PMC/DOI referenced above) — a potential future post-exposure antiviral strategy, not yet in human trials per the sources reviewed. - Small-molecule measles virus RNA polymerase inhibitors have been explored in preclinical/early studies as a strategy to blunt severe disease (PMC2728049 — "Measles control – Can measles virus inhibitors make a difference?"). - Probenecid was recently reported to inhibit Edmonston strain MeV replication in Vero cells in vitro (preprint/early study; requires further validation before clinical relevance can be assessed).

MAXO term suggestions: - MAXO:0000950 (supportive care) — general supportive management - MAXO:0000088 (dietary intervention) — for vitamin A supplementation (or NCIT:C15986 Pharmacotherapy + therapeutic_agent CHEBI vitamin A term if modeled as a drug) - MAXO:0001017 (vaccination) — for MMR post-exposure prophylaxis - Passive immunoglobulin prophylaxis would use NCIT:C15986 Pharmacotherapy with an appropriate immunoglobulin therapeutic_agent term

Sources: Measles Treatment & Management - Medscape, CDC Measles Prevention and Treatment Overview, Vitamin A for treating measles in children - PMC (Cochrane), Nebulized fusion inhibitory peptide protects cynomolgus macaques - Nature Communications, Measles control – Can measles virus inhibitors make a difference? - PMC

13. Prevention

Primary prevention — vaccination: The MMR vaccine (live-attenuated measles, mumps, rubella) is the cornerstone of prevention. Two doses are 97% effective (range 67-100%) at preventing measles; one dose is 93% effective (range 39-100%). The live-attenuated vaccine strain uses CD46 (not SLAM/nectin-4) as its primary receptor, contributing to its attenuated, non-immunosuppressive phenotype relative to wild-type virus — mechanistically consistent with the finding that immune amnesia is not observed in MMR-vaccinated children (Mina et al. 2019).

Herd immunity: Given R0 of ~12-18, elimination requires population immunity of roughly 92-95%, translating to a need for ≥95% two-dose MMR coverage — a threshold current global coverage (83% dose 1 / 74% dose 2) falls well short of, explaining ongoing resurgence.

Secondary prevention: Post-exposure prophylaxis with MMR vaccine (within 72 hours) or immunoglobulin (within 6 days) for high-risk contacts; rapid outbreak-response vaccination campaigns.

Tertiary prevention: Prompt recognition and treatment of complications (antibiotics for secondary bacterial pneumonia/otitis media, vitamin A supplementation, supportive neurological/critical care for encephalitis) to limit sequelae.

Public health interventions: case isolation, contact tracing, outbreak-response immunization, maintenance of high routine MMR coverage, and surveillance/genotyping to track chains of transmission and importation sources.

Screening/risk stratification: verification of vaccination/immunity status (serology) in healthcare workers, international travelers, and outbreak-exposed populations; no genetic carrier or prenatal screening applies.

Counseling: patient/parent education addressing vaccine hesitancy is a major public-health-level "counseling" intervention specific to this disease's current epidemiology, distinct from genetic counseling paradigms used for inherited disease.

Sources: MMR Vaccine - StatPearls, Measles Vaccine Recommendations - CDC, Herd Immunity Threshold Calculator context, Are the Objectives Proposed by WHO Sufficient - PMC

14. Other Species / Natural Disease

Taxonomy: Measles morbillivirus is essentially host-restricted to humans and non-human primates under natural conditions (NCBI Taxon:11234, humans NCBITaxon:9606).

Related morbilliviruses in other species (comparative biology, not measles itself, but mechanistically homologous): - Canine distemper virus (CDV): broad host range among carnivores — wild canids, procyonids (raccoons), ailurids (red pandas), ursids (bears, giant pandas), mustelids (ferrets, minks), viverrids (civets), hyaenids, and large felids (lions, tigers); a major cause of endangered-species mortality (PMC9862170). - Phocine distemper virus (PDV): affects marine mammals (seals); thought to have evolved from CDV via terrestrial-carnivore-to-seal contact. - Cetacean morbillivirus: dolphins/whales. - Peste-des-petits-ruminants virus (small ruminant morbillivirus): sheep and goats. - Rinderpest morbillivirus: historically devastated cattle populations; formally declared eradicated (the second infectious disease, after smallpox, eradicated globally) — a notable "natural experiment" precedent relevant to measles-eradication feasibility discussions.

Morbilliviruses generally are considered among the most infectious viruses known, with morbidity/mortality rates of 90-95% reported in immunologically naive host populations upon introduction (PMC6833027).

Veterinary relevance: CDV is of major veterinary and wildlife-conservation importance (species-jump events into endangered carnivore populations); it is also the most widely used comparative animal-pathogenesis model for measles virus biology given the close genetic and receptor-usage homology (both use SLAM/CD150 and nectin-4 orthologs), described as "Morbillivirus Experimental Animal Models: Measles Virus Pathogenesis Insights from Canine Distemper Virus" (PMC5086610).

Cross-species/zoonotic potential: Measles virus itself is not zoonotic in the classical sense (evolved from rinderpest virus historically, and does not currently circulate in animal reservoirs back to humans); CDV, by contrast, demonstrates ongoing cross-species jumps into diverse carnivore hosts.

Sources: Canine Distemper Virus in Endangered Species - PMC, Canine and Phocine Distemper Viruses: Global Spread and Genetic Basis of Jumping Species Barriers - PMC, Cross-species transmission of canine distemper virus - PubMed, Morbillivirus Experimental Animal Models - PMC

15. Model Organisms

Non-human primate models: Cynomolgus macaques experimentally infected with wild-type MeV show "marked leukopenia associated with a steady reduction in CD4+ T cell numbers for 18 days post-inoculation," making NHPs the model that "best reflect the pathogenesis of measles" among available systems, particularly for immune amnesia/immunosuppression studies. NHP models were also used to test the nebulized fusion-inhibitory-peptide prophylaxis strategy.

Cotton rat (Sigmodon hispidus): A semipermissive small-animal model; cotton rat CD150 was confirmed to function as an entry receptor for MeV with tissue expression patterns similar to mouse and human ("Cotton Rat Signaling Lymphocyte Activation Molecule (CD150) Is an Entry Receptor for Measles Virus," PMC4190324). Wild-type versus vaccine-strain MeV differ in extent of viral spread and immune suppression in this model (PMC140581), making it useful for comparative pathogenicity/attenuation studies, including maternal-antibody interference experiments relevant to vaccine timing.

Transgenic mouse models: Mice engineered to express human CD46 (vaccine-strain receptor) or human CD150/SLAM (wild-type and vaccine-strain receptor) have been developed to "humanize" susceptibility and study MV pathogenicity, since wild-type mice lack functional receptor expression and are naturally non-permissive.

Model limitations: Rodent models (mouse, cotton rat) do not naturally reproduce the full clinical syndrome (rash, Koplik spots) seen in humans/NHPs and generally require receptor-humanization or are only semipermissive; NHP models are the most translationally faithful but are costly and lower-throughput. No single small-animal model fully recapitulates SSPE-type CNS persistence, immune amnesia at full scale, or the characteristic exanthem — a human-model-mismatch-relevant gap worth flagging for a dismech entry (e.g., rodent models chiefly validate receptor biology and short-term immunosuppression, not the complete clinical phenotype).

Research applications: receptor/tropism biology (transgenic mice), immune amnesia/immunosuppression mechanisms (NHP, cotton rat), vaccine/maternal-antibody interaction studies (cotton rat), and antiviral/prophylactic countermeasure testing (NHP nebulized-peptide study).

Comparative model system: Canine distemper virus infection of its natural host (dogs, ferrets) serves as a second-tier "natural disease" comparative model for morbillivirus CNS persistence and pathogenesis given close mechanistic homology (SLAM/nectin-4 receptor usage, similar accessory-protein IFN antagonism strategy) (PMC5086610).

Sources: Immune responses against measles virus in cynomolgus monkeys - ScienceDirect, Cotton Rat CD150 Is an Entry Receptor for Measles Virus - PMC, Extent of Measles Virus Spread and Immune Suppression Differentiates Wild-Type and Vaccine Strains in Cotton Rat Model - PMC, Current animal models: transgenic animal models for measles pathogenesis - PubMed, Morbillivirus Experimental Animal Models - PMC

Summary of Key Ontology Term Suggestions for KB Curation

Note on evidence classification for dismech curation: Human clinical evidence (outbreak cohorts, case series) should be tagged HUMAN_CLINICAL; NHP/cotton rat/transgenic mouse studies MODEL_ORGANISM; VirScan/immunosequencing repertoire analyses on human samples remain HUMAN_CLINICAL (in vivo human sampling, ex vivo assay) rather than IN_VITRO. All PMIDs above should be independently re-verified with just fetch-reference and snippet-matched before use in any KB entry, per the project's anti-hallucination SOP.